|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consistently, the aforementioned associations and the CLU mRNA expression levels are significantly enhanced as CRC tumors progress from TNM stage I to IV, further supporting the functional implication of CLU in tumorigenesis.
|
31672651 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multivariate analysis showed that tumor with macrovascular/microvascular invasion and clusterin expression in nontumor tissues are independent prognostic factors following hepatic resection.
|
31800534 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multivariate analysis showed that tumor with macrovascular/microvascular invasion and clusterin expression in non-tumor tissues are independent prognostic factors following hepatic resection.
|
31567651 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clusterin (CLU) is a glycoprotein involved in inflammation, proliferation, cell death, neoplastic disease, Alzheimer disease and aging.
|
30967152 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both clusterin silencing or VP treatment deterred tumor growth in human GCSC xenografts.
|
30745823 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show that BM-derived CAFs are functionally important for tumor growth and enhance angiogenesis via up-regulation of Clusterin.
|
30470719 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Caki-1/clusterin shRNA clones were injected subcutaneously in nude mice to determine tumour growth and cancer cell invasiveness in vivo.
|
29400663 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor and/or stromal clusterin expression were not associated with patient age, tumor histologic grade, stage, and lymph node status.
|
28890185 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clusterin is frequently, strongly expressed by NETs of diverse anatomic sites, with the exception of jejunoileal tumors, in which it is only rarely, weakly expressed.
|
29420353 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Clu peptide can be detected by antibody in vivo, thus it has the potential to be used to monitor tumor status and treatment efficacy in animal studies and eventually in cancer patients.
|
28076321 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In gastric adenocarcinomas, clusterin mRNA expression was higher in diffuse tumors containing signet ring cells compared with diffuse tumors without signet ring cells, and clusterin seemed to be secreted by tumor cells.
|
28902909 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study demonstrated that integration of proteomics and transcriptomics could prove advantageous for accelerating tumor biomarker discovery and CHGA and CLU might be important novel biomarkers and therapeutic targets for invasion of NFPAs.
|
26753958 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The clinical investigation showed that CLU, MMP-9 and VEGF were positively correlated with the tumor-node -metastasis (TNM) classification.
|
26716898 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells.
|
26988917 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that TRPM2 activity is important for tumor growth and for cell viability and survival following doxorubicin treatment and that interference with TRPM2-L function may be a novel approach to reduce tumor growth through modulation of HIF-1/2α, mitochondrial function, and mitophagy.
|
25391657 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This has led us to focus on molecules associated with resistance, such as the molecular chaperones heat shock proteins (HSPs) and clusterin (CLU), and the cytokines interleukin-6 (IL-6) and the divergent member of the tumor growth factor family MIC-1 (macrophage inhibitory cytokine-1 also named GDF-15).
|
24969394 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To characterize abnormal epigenetic changes and protein expression of the clusterin gene in a large series of ovarian malignant and borderline tumors.
|
23208459 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cotargeting the AR (with MDV3100) and CLU (with OGX-011) synergistically enhanced apoptotic rates over that seen with MDV3100 or OGX-011 monotherapy and delayed CRPC LNCaP tumor and prostate-specific antigen (PSA) progression in vivo.
|
23786771 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The effect of CLU knockdown on GRP78 expression and cell apoptosis in HCC tumors were further determined in orthotopic xenograft tumor model.
|
23457489 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Elevated levels of clusterin (CLU), a stress-induced and secreted cytoprotective chaperone, are associated with advanced tumor stage, metastasis, treatment resistance, and adverse outcome in several cancers.
|
24156019 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The abnormal expression of clusterin is closely related to the occurrence, progression, and prognosis of tumors.
|
24217652 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study implies that MYC tumorigenesis can be effectively antagonized by epigenetic drugs that interfere with the recruitment of chromatin modifiers at repressive E boxes of tumor suppressor genes such as CLU.
|
23362253 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, murine gonadotroph LβT2 tumor cell xenografts overexpressing Clu and FOXL2 both grow slower and elicit smaller tumors.
|
23051594 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stable knockdown of clusterin by vectorbased RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis.
|
22613415 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that secretory clusterin plays a significant role in tumor growth and metastatic progression.
|
23099883 |
2012 |